ARA-290

ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface domain of erythropoietin (EPO). It was engineered by Araim Pharmaceuticals to isolate EPO's tissue-protective and anti-inflammatory properties while eliminating its erythropoietic (red blood cell-stimulating) activity, addressing the safety concerns associated with EPO's hematopoietic effects.

ARA-290 selectively binds to the innate repair receptor (IRR), a heterodimer composed of the EPO receptor and the beta common receptor (CD131/betaCR). This receptor is distinct from the classical EPO receptor homodimer that drives erythropoiesis. IRR activation triggers anti-inflammatory signaling cascades including STAT3 and NF-kB modulation, reduces pro-inflammatory cytokine production, promotes tissue repair, and protects neurons and other cells from apoptosis induced by metabolic stress.

Clinical research has demonstrated ARA-290's efficacy in several conditions. Studies in type 2 diabetes patients showed improved metabolic control and significant relief of neuropathic symptoms, including small fiber neuropathy. Clinical trials have demonstrated improvements in corneal nerve fiber density, indicating nerve regeneration. Research in sarcoidosis showed reduction in inflammatory markers and improved exercise capacity. The peptide has also been studied for chronic inflammatory conditions, surgical recovery, and organ preservation during transplantation. Its clean separation of tissue-protective from erythropoietic effects makes it a promising anti-inflammatory agent without the thrombotic risks associated with EPO.